Patent · US Active

Anti-Siglec-9 antibodies and methods of use thereof

US10800844B2 · kind B2 · utility

1Cited by

57References

23Claims

0Family size

Assignee

Alector LLC

Inventors

Arnon Rosenthal · Woodside, US
Kate Monroe · Berkeley, US
Seung-Joo Lee · Goyang-si, KR

Key dates

Filing date	Oct 28, 2016
Grant date	Oct 13, 2020
Priority date	—
Expiry date	Oct 28, 2036

Classification

Technology area (CPC G)Physics
CPC primaryG01N33/577
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-9 protein, e.g., human Siglec-9 or a mammalian Siglec-9, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.